Genmab A/S (OTCMKTS:GNMSF) Shares Gap Down - Here's What Happened

Key Points

• Shares gapped down: Genmab opened at $272.75 after a $281.06 close, trading down about 8.6% with only 71 shares reported at the last trade.
• Quarterly earnings missed: The company reported EPS of $0.55 versus analysts' $3.10 consensus (a $2.55 miss), while revenue was $1.06 billion, slightly above the $1.05 billion estimate.
• Solid underlying fundamentals: Genmab has a market cap of about $16.8 billion, a P/E of 17.6, strong liquidity (current and quick ratios ~2.0) and healthy profitability (net margin ~25.9%, ROE ~17.4%).

Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s stock price gapped down prior to trading on Friday . The stock had previously closed at $281.06, but opened at $272.75. Genmab A/S shares last traded at $272.75, with a volume of 71 shares.

Genmab A/S Trading Down 8.6%

The company has a current ratio of 2.02, a quick ratio of 2.01 and a debt-to-equity ratio of 0.86. The stock has a 50 day simple moving average of $288.43 and a 200-day simple moving average of $305.58. The firm has a market cap of $16.79 billion, a P/E ratio of 17.62 and a beta of 0.94.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last released its quarterly earnings data on Tuesday, February 17th. The company reported $0.55 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.10 by ($2.55). The firm had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.05 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.

About Genmab A/S

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company's core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab's science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.